openPR Logo
Press release

Download Global Hepatitis Drug Market and Clinical Trials Insight 2023 Report

09-14-2017 08:02 AM CET | Health & Medicine

Press release from: Kuick Resarch

Download Global Hepatitis Drug Market and Clinical Trials

“Global Hepatitis Drug Market and Clinical Trials Insight 2023” report gives comprehensive insight on various clinical and non-clinical advancements in the global Hepatitis drug market. Currently, there are 321 Hepatitis drugs in clinical pipeline and 110 Hepatitis drugs are commercially available in the market. Hepatitis drug clinical trials landscape is dominated by Hepatitis C drug with 145 drugs in various phases of development and 25 drugs commercially available in the market. The overall Hepatitis drug revenues are expected to surpass US$ 70 Billion by 2023 with major share accounted by Hepatitis C drugs.

“Global Hepatitis Drug Market and Clinical Trials Insight 2023” report highlights:

Prevalence of Hepatitis Infection
Available Drug Classes for Hepatitis Drug
Global Hepatitis Drug Market Analysis
Global Hepatitis (A,B,C,D and E) Drug Clinical Pipeline Insight
Marketed Hepatitis Drug Clinical Insight by Drug Class
Future Perspective of Hepatitis Therapeutics

Hepatitis virus infection lies among primary public health threats globally and is basically a main reason for the development of liver cirrhosis and hepatocellular carcinoma. The incidence and prevalence of hepatitis viral infection is growing and increases the burden. However, the worldwide remains unknown due to heterogeneous registration and case definitions. There are several subcategories of viruses which cause the infection or inflammation to liver and these subgroups are hepatitis A virus, hepatitis B virus, hepatitis C virus, hepatitis D virus and hepatitis E virus. The investigation for other subcategory of viruses is ongoing. Hepatitis B virus and hepatitis C virus are main leading causes of liver diseases.

The past two decades have witnessed substantial progress in the treatment of hepatitis virus infection and it includes the introduction of nucleotides and nucleoside analogues, interferons, toll like receptors and protease inhibitors which revolutionized the hepatitis disease management.

With the recent dramatic progress in development of potent antiviral drugs for chronic hepatitis virus infection, virological responses are achievable in almost all patients. Most clinical practice guidelines strongly recommended the treatment of patients with antiviral agents if they have proper indications. The main aim of antiviral treatment is to inhibit the hepatitis virus replication and improve the liver pathology but it rarely cures chronic hepatitis infection.

The global hepatitis drug market is expected to surpass USD 70 Billion by 2023 with the rising number of infected population, growing consumption of alcohol and drugs and the improvement in the access to hepatitis medicines. The introduction of generic drugs of hepatitis has also changed the market dynamics across the globe. With the increase of people being able to afford the generic versions, the usage rates of drugs are expected to grow rapidly over the next few years.

For Report Sample Contact: neeraj@kuickresearch.com

Report Weblink: https://www.kuickresearch.com/report-global-hepatitis-drug-market-and-clinical-trials-insight-2023.php

1. Introduction to Hepatitis Disease
1.1 Prologue
1.1.1 History of Hepatitis
1.1.2 Causes of Hepatitis Disease
1.2 Types of Viruses which are Responsible for Hepatitis Disease

2. Global Prevalence of Hepatitis Infection

3. Available Drug Classes for Hepatitis Disease Treatment
3.1 Interferon Alfa Therapy
3.2 Protease Inhibitors Therapy
3.3 Polymerase Inhibitors Therapy
3.4 Toll like Receptor Agonists Therapy

4. Global Hepatitis Drug Market Analysis
4.1 Introduction
4.2 Global Hepatitis Drug Market Insight

5. Global Hepatitis Drug Market Dynamics
5.1 Favorable Market Parameters
5.2 Market Challenges

6. Future Perspective of Hepatitis Therapeutics

7. Global Hepatitis Drug Clinical Pipeline Overview
7.1 Hepatitis A
7.2 Hepatitis B
7.3 Hepatitis C
7.4 Hepatitis D
7.5 Hepatitis E

8. Hepatitis A Drug Clinical Trials Insight by Phase and Drug Class (5 Drugs)
8.1 Research
8.2 Preclinical
8.3 Clinical
8.4 Phase-III

9. Marketed Hepatitis A Drug Clinical Insight by Drug Class (12 Drugs)

10. Hepatitis B Drug Clinical Trials Insight by Phase and Drug Class (134 Drugs)
10.1 Unknown
10.2 Research
10.3 Preclinical
10.4 Clinical
10.5 Phase-I
10.6 Phase-I/II
10.7 Phase-II
10.8 Phase-II/III
10.9 Phase-III
10.10 Preregistration
10.11 Registered

11. Marketed Hepatitis B Drug Clinical Insight by Drug Class (46 Drugs)

12. Hepatitis C Drug Clinical Trials Insight by Phase and Drug Class (145 Drugs)
12.1 Unknown
12.2 Research
12.3 Preclinical
12.4 Clinical
12.5 Phase-I
12.6 Phase-I/II
12.7 Phase-II
12.8 Phase-II/III
12.9 Phase-III
12.10 Preregistration
12.11 Registered

13. Marketed Hepatitis C Drug Clinical Insight by Drug Class (25 Drugs)
13.1 ZEPATIER
13.2 Harvoni
13.3 Victrelis
13.4 Copegus
13.5 Sovaldi
13.6 Vanihep
13.7 Incivek
13.8 Olysio
13.9 VIEKIRA
13.10 Infergen
13.11 Viekirax
13.12 Epclusa
13.13 Ximency
13.14 Daclatasvir + Asunaprevir Combination
13.15 Peginterferon Alfa-2b (Y-shaped pegylation)
13.16 Golotimod
13.17 Algeron
13.18 Pegetron
13.19 Rebetron
13.20 IBAVYR
13.21 Reiferon Retard
13.22 Reiferon - Interferon Alpha-2a Biosimilar
13.23 Interferon Alpha-2a
13.24 Glycyron Tablets
13.25 Daklinza

14. Hepatitis D Drug Clinical Trials Insight by Phase and Drug Class (4 Drugs)
14.1 Research
14.2 Preclinical
14.3 Phase-II

15. Hepatitis E Drug Clinical Trials Insight by Phase and Drug Class ( 2 Drugs)
15.1 Preclinical
15.2 Phase-I

16. Marketed Hepatitis E Drug Clinical Insight by Drug Class (1 Drug)

17. Multiple Hepatitis Drug Clinical Trials Insight by Phase and Drug Class (31 Drugs)
17.1 Unknown
17.2 Research
17.3 Preclinical
17.4 Clinical
17.5 Phase-I
17.6 Phase-I/II
17.7 Phase-II
17.8 Preregistration

18. Marketed Multiple Hepatitis Drug Clinical Insight by Drug Class (26 Drugs)

19. Competitive Landscape
19.1 Arbutus Biopharma
19.2 Biostar Pharmaceuticals
19.3 Bristol-Myers Squibb
19.4 GlaxoSmithKline
19.5 Gilead Sciences
19.6 Enanta
19.7 Achillion
19.8 Presidio
19.9 Benitec Biopharma
19.10 Janssen Pharmaceuticals
19.11 AbbVie
19.12 Merck
19.13 Novira Therapeutics
19.14 Contravir
19.15 VBI Vaccines

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

KuicK Research
New Delhi - 110001
India
+91-11-47067990

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Download Global Hepatitis Drug Market and Clinical Trials Insight 2023 Report here

News-ID: 715589 • Views:

More Releases from Kuick Resarch

Lumakras Drug Clinical Insight and Sales Forecast 2026
Lumakras Drug Clinical Insight and Sales Forecast 2026
"Lumakras Drug Clinical Insight and Sales Forecast 2026" Report Highlights: * NSCLC Targeting Lumakras Market Opportunity (US$ Million) * Colorectal Cancer Targeting Lumakras Market Opportunity (US$ Million) * Pharmacokinetics of Lumakras (Sotorasib) * Dosage, Patent and Price Analysis * Lumakras Ongoing Clinical Trials * Global KRAS Protein Inhibitors Clinical Trials Download Report: https://www.kuickresearch.com/report-lumakras-sotorasib-sales-forecast-fda-approved-kras-inhibitor-clinical-trials-non-small-cell-lung-cancer-nslc-g12c-mutation-c30h30f2n6o3-ras-gtpase The rising burden of cancer and the increasing cancer mortality rates possesses an unmet need for the development of novel therapies in the management
Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026
Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026
"Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026" Report Highlights: * Global EZH2 Inhibitor Market Opportunity > US$ 1.2 Billion by 2026 * Tazverik (Tazemetostat) First Approved EZH2 Inhibitor Drug * Dosage, Price and Sales Analysis of Tazverik * Tazverik Sales Opportunity > US$ 900 Million by 2026 * Tazverik Sales Forecast 2021 Till 2026 * EZH2 Inhibitor Clinical Pipeline Overview By Company, Indication and Phase * EZH2 Inhibitor in Clinical Trials: 7 Drugs Download
Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028
Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Tr …
"Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028" Report Highlights: * Global Bispecific Antibody Market Opportunity: > US$ 20 Billion * Global Bispecific Antibody Market Growth Rate: 100% CAGR (2016 -2021) * Approved Bispecific Antibodies In Market: 4 Antibodies * Detailed Market Sales and Trends Insight Till 2028 * Quarterly and Yearly Sales Insight Of Approved Antibodies Till Q1 2022 * Global and Regional Market Analysis * Approved Drug Sales
Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026
Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and C …
"Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026" Report Highlights: * Global FGFR Inhibitors Market Opportunity: > USD 4 Billion by 2026 * Role of FGFR Inhibitors in Cancer Therapy * Global FGFR Market Assessment (US$) by Region and Cancer Type Clinical and Sales Insight on Approved FGFR Inhibitors: 3 (Belvesra, Pemazyre and Truseltiq) * Dosage and Drug Price Insight on Approved FGFR Inhibitors * Comprehensive Clinical Trials Insight

All 5 Releases


More Releases for Drug

Alcohol Testing And Drug Testing Equipment Market 2025 Segmentation, Application …
Market Study Report, LLC, has compiled an exhaustive research study of the ‘Alcohol Testing And Drug Testing Equipment market’, detailing every single market driver and intricately analyzing the business vertical. This ‘Alcohol Testing And Drug Testing Equipment market’ study will aid in seeking out new business opportunities and fine-tuning existing marketing strategies through insights regarding SWOT analysis, market valuation, competitive spectrum, regional share, and revenue predictions. Alcohol abuse and drug
How much Diabetes Drug Market Impact Worldwide Medical Drug Industry?
Diabetes Drug Market From an insight perspective, the market report focuses on various levels of analyses — industry analysis, market rank analysis, and company profiles, which together comprise and discuss basic views on the competitive landscape, high-growth regions, and countries as well as their respective regulatory policies, Types ,Applications and opportunities in the market.  Diabetes is a metabolic disorder in which the body glucose level is elevated. There are two types of diabetes
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue 1.1.1 History of Hepatitis 1.1.2 Causes of Hepatitis Disease 1.2 Types of Viruses which are Responsible for Hepatitis Disease 2. Global Prevalence of Hepatitis Infection 3. Available Drug Classes for Hepatitis Disease Treatment 3.1 Interferon Alfa Therapy 3.2 Protease Inhibitors Therapy 3.3 Polymerase
Microcapsules Drug Delivery Market Microcapsules Drug Delivery Sales Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Indispensable Advent of Microcapsules 1.1 Trajectory of Microencapsulation 1.2 Why and wherefores for Microencapsulation 2. Characterization of Microcapsules 2.1 Composition of Microcapsules 2.2 Parameters Influencing Microcapsules 3. Engineering Technology of Microcapsules 3.1 Physical Manufacturing Technologies 3.2 Physicochemical and Chemical Technologies 4. Applicability of Microcapsules 4.1 Microcapsules in Pharmaceuticals 4.2 Microcapsules in Nutraceuticals
AstraZeneca’s NMOSD Drug receives orphan drug designation
April 18, 2017 Orphan Drug European Medicine Agency has Announced orphan drug designation for inebilizumab (earlier known as MEDI-551) developed by AstraZeneca PLC (AZN) for the treatment of neuromyelitis optica spectrum disorder (NMOSD). The drug has already received orphan drug status from US Food and Drug Administration (FDA). NMOSD, also called Devic’s disease, is a rare, autoimmune disorder of the central nervous system (CNS) that affects the functioning
Drug Discovery Strategies, PBPK Modeling and Drug-Drug Interaction Explored and …
This year’s 12th annual ADMET conference and exhibition promises to deliver appearances from experienced pharmaceutical professionals from ADME and PK/PD organisations such as AbbVie, GSK, Roche and Bayer when it returns to London this June. The carefully selected speaker line up will be addressing early ADME application strategies and discussing the latest technologically advanced screening and testing models along with exploring ADMET technologies which will identify properties of a drug